Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.

Blood cancer journal - 13 Jun 2024

Hirsch Pierre, Lambert Jérôme, Bucci Maxime, Deswarte Caroline, Boudry Augustin, Lambert Juliette, Fenwarth Laurene, Micol Jean-Baptiste, Terré Christine, Celli-Lebras Karine, Thomas Xavier, Dombret Hervé, Duployez Nicolas, Preudhomme Claude, Itzykson Raphael, Delhommeau Francois

Abstract excerpt

The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated in several studies. However controversial results exist regarding the detection of persisting mutations in DNMT3A, TET2, and ASXL1 (DTA). Benchmarking of NGS-MRD taking into account other molecular MRD strategies has to be done. Here,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA (Cytosine-5-)-Methyltransferases
Share to DNA Methyltransferase 3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Prognosis

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 38871702
DOI: 10.1038/s41408-024-01078-8
PMCID: PMC11176326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.PMID 38871702Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemiaSemantic proximity Read ↗

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.Semantic proximity Read ↗

Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemiaSemantic proximity Read ↗

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.Semantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.Semantic proximity Read ↗

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.